A Study of RO7105705 in Patients With Moderate Alzheimer's Disease



Status:Recruiting
Conditions:Alzheimer Disease
Therapuetic Areas:Neurology
Healthy:No
Age Range:50 - 85
Updated:4/4/2019
Start Date:January 30, 2019
End Date:September 24, 2021
Contact:Reference Study ID Number: GN40040 www.roche.com/about_roche/roche_worldwide.htm
Email:global-roche-genentech-trials@gene.com
Phone:888-662-6728 (U.S. and Canada)

Use our guide to learn which trials are right for you!

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease

This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group
study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of
RO7105705 in patients with moderate AD. The study consists of a screening period, a
double-blind treatment period, an optional open-label extension (OLE) period, and a safety
follow-up period.


Inclusion Criteria:

- National Institute on Aging/Alzheimer's Association core clinical criteria for
probable AD dementia

- Evidence of the AD pathological process, by a positive amyloid assessment either on
CSF Aβ1-42 as measured on Elecsys β-Amyloid(1-42) Test System OR amyloid PET scan

- AD dementia of moderate severity, as defined by a screening MMSE score of 16-21
points, inclusive, and a CDR-GS of 1 or 2

- Availability of a person with sufficient contact with the participant to be able to
provide accurate information on the participant's cognitive, behavioral and functional
ability

Exclusion Criteria:

- Pregnant or breastfeeding

- Inability to tolerate MRI procedures or contraindication to MRI

- Contraindication to PET imaging

- Residence in a skilled nursing facility

- Any serious medical condition or abnormality in clinical laboratory tests that, in the
investigator's judgment, precludes the patient's safe participation in and completion
of the study, or bias the assessment of the clinical or mental status of the
participant to a significant degree

- Any evidence of a condition other than AD that may affect cognition

- Substance abuse within the past 2 years

- Use of any experimental therapy within 90 days or 5 half-lives prior to screening,
whichever is greater, or any passive immunotherapy against tau

- Use of any passive immunotherapy (immunoglobulin) against Aβ, unless the last dose was
at least 1 year prior to screening or any active immunotherapy (vaccine) that is under
evaluation to prevent or postpone cognitive decline

- Any other biologic therapy or previous treatment with medications specifically
intended to treat Parkinsonian symptoms or any other non-AD neurodegenerative disorder
within 1 year of screening

- Systemic immunosuppressive therapy within 12 months of screening through the entire
study period

- Typical antipsychotic or neuroleptic medication within 6 months of screening

- Daily treatment with any of the following classes of medication (except for
intermittent short-term use): opiates or opioids, benzodiazepines, barbiturates,
hypnotics, or any medication with clinically significant centrally-acting
antihistamine or anticholinergic activity

- Stimulant medications, unless the dose has been stable within the 6 months prior to
screening and is expected to be stable throughout the study
We found this trial at
18
sites
Elk Grove Village, Illinois 60007
?
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
3924 9th Avenue West
Bradenton, Florida 34205
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
Atlantis, Florida 33462
?
mi
from
Atlantis, FL
Click here to add this to my saved trials
Bennington, Vermont 05201
?
mi
from
Bennington, VT
Click here to add this to my saved trials
1653 West Congress Parkway
Chicago, Illinois 60612
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Delray Beach, Florida 33445
?
mi
from
Delray Beach, FL
Click here to add this to my saved trials
East Providence, Rhode Island 02914
?
mi
from
East Providence, RI
Click here to add this to my saved trials
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Knoxville, Tennessee 37920
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Lake Worth, Florida 33449
?
mi
from
Lake Worth, FL
Click here to add this to my saved trials
Orlando, Florida 32806
?
mi
from
Orlando, FL
Click here to add this to my saved trials
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Quincy, Massachusetts 02169
?
mi
from
Quincy, MA
Click here to add this to my saved trials
?
mi
from
Rennes,
Click here to add this to my saved trials
?
mi
from
Stamford, CT
Click here to add this to my saved trials
Toms River, New Jersey 08757
?
mi
from
Toms River, NJ
Click here to add this to my saved trials
West Palm Beach, Florida 33407
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Willow Grove, Pennsylvania 19090
?
mi
from
Willow Grove, PA
Click here to add this to my saved trials